285 related articles for article (PubMed ID: 28586118)
1. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S
APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118
[TBL] [Abstract][Full Text] [Related]
2. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.
Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE
PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997
[TBL] [Abstract][Full Text] [Related]
3. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.
Lin HH; Ke HL; Wu WJ; Lee YH; Chang LL
Urol Oncol; 2012; 30(2):177-81. PubMed ID: 20800513
[TBL] [Abstract][Full Text] [Related]
5. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
[TBL] [Abstract][Full Text] [Related]
6. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.
Reinert T; Borre M; Christiansen A; Hermann GG; Ørntoft TF; Dyrskjøt L
PLoS One; 2012; 7(10):e46297. PubMed ID: 23056278
[TBL] [Abstract][Full Text] [Related]
10. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim JS; Kang HW; Min BD; Kim SK; Ha YS; Kim IY; Ryu KH; Lee SC; Kim WJ
Int J Cancer; 2013 Sep; 133(5):1135-42. PubMed ID: 23436614
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
Zhang C; Xu X; Wang T; Lu Y; Lu Z; Wang T; Pan Z
Sci Rep; 2024 Apr; 14(1):7941. PubMed ID: 38575639
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients.
El Azzouzi M; El Ahanidi H; Hafidi Alaoui C; Chaoui I; Benbacer L; Tetou M; Hassan I; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
Cancer Genet; 2022 Jan; 260-261():41-45. PubMed ID: 34922269
[TBL] [Abstract][Full Text] [Related]
14. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
15. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703
[TBL] [Abstract][Full Text] [Related]
16. A global profile of gene promoter methylation in treatment-naïve urothelial cancer.
Ibragimova I; Dulaimi E; Slifker MJ; Chen DY; Uzzo RG; Cairns P
Epigenetics; 2014 May; 9(5):760-73. PubMed ID: 24521710
[TBL] [Abstract][Full Text] [Related]
17. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
[TBL] [Abstract][Full Text] [Related]
18. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
19. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
20. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
